Cue Biopharma (CUE) Financials: History & Chart

Cue Biopharma, Inc.(CUE)

Biotechnology · Boston, MA

$23.10-1.26 (-5.17%)

Delayed quote: Oct 6, 2026, 3:45 PM EDT

About Cue Biopharma, Inc.

Cue Biopharma, Inc. is a clinical-stage biopharmaceutical enterprise focused on creating biological therapies. Its central objective is the precise manipulation of the human immune system to address a spectrum of severe conditions, such as various cancers, chronic infectious diseases, and autoimmune disorders. The company's leading investigational therapeutic is CUE-101, a specialized fusion protein biologic. This candidate is currently advancing through Phase 1b clinical trials, engineered to specifically identify and activate antigen-specific T cells involved in cancers originating from human papillomavirus. Beyond its flagship program, Cue Biopharma is also developing a range of other innovative platforms: CUE-102, another fusion protein biologic designed to stimulate specific T cells to combat cancer; CUE-103, an Immuno-STAT from the CUE-100 series, which is developed to target the KRAS G12V mutation relevant in diseases like colorectal, lung, and pancreatic cancers; CUE-200, which concentrates on cell surface receptors such as CD80 and/or 4-1BBL to counteract T cell exhaustion often seen in chronic infections; and the CUE-300 and CUE-400 frameworks, conceptual platforms aimed at treating diverse autoimmune conditions. Cue Biopharma maintains key strategic alliances, including collaborations with Merck Sharp & Dohme Corp. for the research and development of its unique biologics targeting autoimmune indications, with LG Chem Life Sciences for advancing Immuno-STATs in the field of oncology, and with the Albert Einstein College of Medicine. The company, founded in 2014, was initially known as Imagen Biopharma, Inc. before adopting its current name, Cue Biopharma, Inc., in October 2016. It is headquartered in Cambridge, Massachusetts.

Boston, MA

29 employees

www.cuebiopharma.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Shao-Lee Lin

View full financials

Financials

SEC Filings

Quarterly Income Statement (USD)

Swipe horizontally to review earlier periods. The line-item column stays pinned.

Quarterly Report	TTM	Quarter ended Jun 2026	Quarter ended Mar 2026	Quarter ended Dec 2025	Quarter ended Sep 2025	Quarter ended Jun 2025	Quarter ended Mar 2025	Quarter ended Dec 2024	Quarter ended Sep 2024
Revenue	37.65M	7.88M	5.69M	21.94M	2.15M	2.95M	421K	1.58M	3.34M
Cost of Goods Sold	115K	36K	0.00	0.00	79K	0.00	0.00	0.00	0.00
Gross Profit	37.54M	7.84M	5.69M	21.94M	2.07M	2.95M	421K	1.58M	3.34M
Gross Profit Margin	99.7%	99.5%	100.0%	100.0%	96.3%	100.0%	100.0%	100.0%	100.0%
Total Operating Expenses	136.22M	95.57M	11.05M	19.98M	9.61M	11.59M	12.72M	11.21M	12.15M
Research & Development	77.12M	49.01M	6.90M	16.53M	4.69M	7.91M	8.55M	7.18M	9.38M
Selling, General & Administrative	59.10M	46.56M	4.15M	3.45M	4.93M	3.67M	4.17M	4.02M	2.87M
Operating Income (EBIT)	-98.64M	-87.69M	-5.36M	1.96M	-7.54M	-8.63M	-12.30M	-9.63M	-8.81M
Operating Margin	-262.0%	-1113.3%	-94.3%	8.9%	-351.0%	-292.3%	-2921.4%	-611.2%	-264.2%
Income Before Tax (EBT)	-163.61M	-153.07M	-5.18M	2.08M	-7.45M	-8.48M	-12.26M	-9.50M	-8.66M
Interest Income	716K	157K	179K	158K	222K	198K	170K	290K	343K
Interest Expense	135K	5K	4K	51K	75K	45K	128K	153K	188K
Other Income/Expense	-64.96M	-65.37M	185K	127K	96K	153K	42K	137K	155K
Net Income	-164.11M	-153.07M	-5.18M	1.58M	-7.45M	-8.48M	-12.26M	-9.50M	-8.66M
Income Tax Expense	500K	0.00	0.00	500K	0.00	0.00	0.00	0.00	0.00
Net Profit Margin	-435.8%	-1943.2%	-91.1%	7.2%	-346.6%	-287.1%	-2911.4%	-602.5%	-259.6%
EBITDA	-96.39M	-87.66M	-4.43M	3.16M	-7.46M	-7.84M	-11.42M	-9.54M	-7.94M
EBITDA Margin	-256.0%	-1112.8%	-78.0%	14.4%	-347.4%	-265.4%	-2711.9%	-605.0%	-237.9%
Depreciation & Amortization	2.25M	36K	929K	1.21M	79K	796K	882K	98K	877K
EPS Basic	-26.99	-24.14	-1.08	0.44	-2.21	-2.66	-5.10	-3.90	-5.10
EPS Diluted	-27.00	-24.14	-1.08	0.43	-2.21	-2.66	-5.10	-3.90	-5.10
Weighted Average Basic Shares	6.34M	6.34M	4.81M	3.60M	3.36M	3.18M	2.48M	2.47M	1.71M
Weighted Average Diluted Shares	6.34M	6.34M	4.81M	3.68M	3.36M	3.18M	2.48M	2.47M	1.71M

Annual Income Statement (USD)

Swipe horizontally to review earlier years. The line-item column stays pinned.

Annual Report	12/31/2025	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018
Revenue	27.47M	9.29M	5.49M	1.25M	14.94M	3.15M	3.46M	1.14M
Cost of Goods Sold	0.00	0.00	38.10M	0.00	-1.78M	33.55M	27.49M	28.54M
Gross Profit	27.47M	9.29M	-32.61M	1.25M	16.72M	-30.39M	-24.03M	-27.40M
Gross Profit Margin	100.0%	100.0%	-593.9%	100.0%	111.9%	-963.5%	-694.8%	-2398.2%
Total Operating Expenses	53.99M	50.79M	19.54M	54.47M	60.43M	14.65M	12.74M	39.84M
Research & Development	37.74M	36.30M	40.80M	38.58M	41.35M	33.55M	27.49M	28.54M
Selling, General & Administrative	16.24M	14.59M	16.68M	16.17M	17.31M	14.65M	12.74M	11.30M
Operating Income (EBIT)	-26.52M	-41.50M	-52.15M	-53.23M	-43.71M	-45.04M	-36.77M	-38.70M
Operating Margin	-96.6%	-446.9%	-949.9%	-4275.1%	-292.6%	-1428.0%	-1063.2%	-3386.7%
Income Before Tax (EBT)	-26.10M	-40.67M	-50.73M	-53.01M	-43.67M	-44.58M	-36.29M	-38.16M
Interest Income	807K	1.62M	2.66M	928K	46K	464K	419K	376K
Interest Expense	357K	796K	1.25M	714K	N/A	N/A	N/A	N/A
Other Income/Expense	419K	826K	1.42M	215K	46K	464K	483K	541K
Net Income	-26.60M	-40.67M	-50.73M	-53.01M	-44.16M	-44.78M	-36.70M	-38.98M
Income Tax Expense	500K	0.00	0.00	0.00	495K	206K	413K	825K
Net Profit Margin	-96.9%	-438.0%	-924.1%	-4257.8%	-295.6%	-1419.8%	-1061.2%	-3411.5%
EBITDA	-23.04M	-39.15M	-48.71M	-51.42M	N/A	-43.99M	-35.96M	-37.94M
EBITDA Margin	-83.9%	-421.6%	-887.3%	-4130.0%	N/A	-1394.4%	-1039.8%	-3320.2%
Depreciation & Amortization	3.48M	2.35M	3.44M	1.81M	-1.78M	1.06M	811K	760K
EPS Basic	-8.40	-21.60	-33.30	-44.70	-42.30	-46.80	-49.80	-58.20
EPS Diluted	-8.40	-21.60	-33.30	-44.70	-42.30	-46.80	-49.80	-58.20
Weighted Average Basic Shares	3.16M	1.88M	1.53M	1.19M	1.04M	956K	735K	671K
Weighted Average Diluted Shares	3.16M	1.88M	1.53M	1.19M	1.04M	956K	735K	671K

Values are displayed in USD. Negative numbers shown in red.

Values are displayed in USD. Negative numbers are shown in red.